OPEN END TURBO BULL OPTIONSSCHEIN - ASTRAZENECA | Real-time BOERSE MUENCHEN 12:46:51 20/06/2024 BST | ||
| 6.83 EUR | +0.29% |
|
| Current month | +2.87% | ||
| 1 month | +5.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 6.83 | +0.29% |
| 19/06/24 | 6.81 | -0.87% |
| 18/06/24 | 6.87 | -0.72% |
| 17/06/24 | 6.92 | -1.56% |
| 14/06/24 | 7.03 | +2.33% |
Real-time BOERSE MUENCHEN
Last update June 20, 2024 at 12:46 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR778R |
| ISIN | DE000HR778R8 |
| Date issued | 04/05/2021 |
| Strike | 6,605 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.17 € |
|---|---|
| Lowest since issue | 2.02 € |
| Spread | 0.01 € |
| Spread % | 0.15% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157
USD
Average target price
174.4
USD
Spread / Average Target
+11.09%
- Stock Market
- Certificates
- Certificat
